Welcome to our dedicated page for Travere Therapeutics SEC filings (Ticker: TVTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Travere Therapeutics, Inc. filings document a rare-disease biopharmaceutical issuer whose disclosures center on FILSPARI (sparsentan), operating results, FDA regulatory events, and public-company governance. Recent 8-K reports furnish quarterly and annual financial results and disclose regulatory events involving FILSPARI in focal segmental glomerulosclerosis and IgA nephropathy.
Proxy materials cover annual meeting voting, board matters, executive compensation, equity awards, and stockholder governance. The filing record also documents formal event reporting under the Exchange Act for product-regulatory updates and financial-condition disclosures.
Travere Therapeutics, Inc. director Ruth Williams Brinkley received an automatic equity grant under the company’s 2018 Equity Incentive Plan pursuant to its non-employee director compensation program. The award includes 4,000 shares of common stock and stock options for 12,000 shares at an exercise price of $42.26 per share.
The equity award vests over a one-year period. The stock options become exercisable beginning on May 19, 2027 and expire on May 19, 2036. Following the stock grant, Brinkley directly holds 29,750 shares of Travere Therapeutics common stock.
Travere Therapeutics director Ron Squarer received new equity compensation. He was granted 4,000 shares of common stock as an automatic equity grant under the company’s 2018 Equity Incentive Plan, pursuant to the non-employee director compensation program. Following this award, he directly holds 39,375 common shares.
Squarer was also granted stock options covering 12,000 shares of common stock with a conversion price of $42.26 per share. The equity award vests over a one-year period, and the options are exercisable from May 2027 and expire in May 2036, reflecting routine board-level compensation rather than open-market trading.
Travere Therapeutics director Sandra Poole received equity compensation in the form of shares and options. On May 19, 2026, she was granted 4,000 shares of common stock at no cost under Travere’s 2018 Equity Incentive Plan as part of the non-employee director compensation program. Following this grant, she directly holds 34,000 common shares. On the same date, she also received a stock option for 12,000 shares of common stock with an exercise price of $42.26 per share, expiring in 2036. The award vests over one year, indicating a time-based service requirement rather than an open-market purchase.
Travere Therapeutics director John A. Orwin reported equity awards. He received 4,000 shares of common stock as an automatic equity grant under Travere’s 2018 Equity Incentive Plan, pursuant to the non-employee director compensation program. Following this award, he directly holds 39,375 common shares.
Orwin was also granted stock options for 12,000 shares of common stock at an exercise price of $42.26 per share. These options begin exercisability on May 19, 2027, expire on May 19, 2036, and the equity award vests over one year.
Meckler Jeffrey A reported acquisition or exercise transactions in this Form 4 filing.
Travere Therapeutics director Jeffrey A. Meckler received new equity compensation. He was granted 4,000 shares of common stock and 12,000 stock options as an automatic equity grant under Travere’s 2018 Equity Incentive Plan and non-employee director compensation program.
The options give him the right to buy 12,000 shares of common stock at $42.26 per share and expire on May 19, 2036. The equity award vests over a one year period. After the grant, he directly owns 91,500 common shares and holds 12,000 stock options.
Travere Therapeutics director Gary A. Lyons received new equity awards as part of his board compensation. He was granted 4,000 shares of common stock at no cost under the company’s 2018 Equity Incentive Plan for non-employee directors, increasing his direct holdings to 61,500 shares.
Lyons was also granted stock options for 12,000 shares of common stock at an exercise price of $42.26 per share, expiring in 2036. The equity award vests over a one year period, making this a routine, compensation-related acquisition rather than an open-market purchase.
Travere Therapeutics, Inc. director Timothy Coughlin reported receiving equity compensation consisting of common shares and stock options. On May 19, 2026, he was granted 4,000 shares of Common Stock, increasing his direct holdings to 56,250 shares. He was also granted stock options for 12,000 shares of Common Stock at an exercise price of $42.26 per share, exercisable starting May 19, 2027 and expiring on May 19, 2036. The filing notes these are automatic equity grants under Travere’s 2018 Equity Incentive Plan for non-employee director compensation, with the equity award vesting over one year.
Travere Therapeutics director Suzanne Louise Bruhn received new equity awards as part of the company’s non-employee director compensation program. She was granted 4,000 shares of common stock, bringing her direct holdings to 32,750 shares after the transaction. She also received stock options covering 12,000 shares of common stock at an exercise price of $42.26 per share. The filing states these awards were automatic grants under Travere’s 2018 Equity Incentive Plan and that the equity award vests over a one-year period.
Baynes Roy D. reported acquisition or exercise transactions in this Form 4 filing.
Travere Therapeutics director Roy D. Baynes received new equity compensation awards. He was granted 4,000 shares of common stock at no cost and a stock option covering 12,000 shares with a strike price of $42.26 per share.
The awards were made as an automatic equity grant under Travere’s 2018 Equity Incentive Plan pursuant to the non-employee director compensation program. The equity award vests over one year, and following the stock grant Baynes directly holds 41,500 shares of common stock.
Travere Therapeutics, Inc. held its 2026 Annual Meeting of Stockholders, where stockholders approved an amendment to the 2018 Equity Incentive Plan to authorize an additional 3,000,000 shares of common stock for equity awards. All ten director nominees were elected, executive compensation received advisory approval, and stockholders indicated a preference for annual advisory votes on pay. Stockholders also ratified Ernst & Young LLP as independent auditor for the fiscal year ending December 31, 2026.